THAL SNS 032
CAS: 2139287-33-3
Rif. 3D-PKD28733
| 1mg | Fuori produzione | ||
| 5mg | Fuori produzione | ||
| 10mg | Fuori produzione | ||
| 25mg | Fuori produzione | ||
| 50mg | Fuori produzione |
Informazioni sul prodotto
THAL SNS 032 is a cancer drug that binds to the bromodomain of the BRD4 protein and inhibits its function. This drug has a potential mechanism for the treatment of cancers, which may be due to its ability to induce apoptosis in cancer cells without affecting healthy cells. THAL SNS 032 also inhibits the growth of many types of cancer by inhibition of growth factor signaling and inducing autophagy, which is a process that removes damaged proteins and organelles from cells. THAL SNS 032 also blocks the activation of transcription factors such as NF-κB, leading to suppression of inflammatory responses. It also has an effect on autoimmune diseases by blocking TNF-α receptor activity, which can lead to decreased inflammation in autoimmune diseases like rheumatoid arthritis.
